about
Genetic divergence of influenza A NS1 gene in pandemic 2009 H1N1 isolates with respect to H1N1 and H3N2 isolates from previous seasonal epidemicsSystematic analysis of human oncogenic viruses in colon cancer revealed EBV latency in lymphoid infiltrates.The PDZ-ligand and Src-homology type 3 domains of epidemic avian influenza virus NS1 protein modulate human Src kinase activity during viral infection.Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors.Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement.Assays for determination of HIV resistance to antiviral drugs.Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infectionNaturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages.Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study groupGenotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy.Development and persistence of DAA resistance associated mutations in patients failing HCV treatment.Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation.Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life.HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.Detection and pathogenicity of human metapneumovirus respiratory infection in pediatric Italian patients during a winter--spring season.Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing.The novel influenza A virus protein PA-X and its naturally deleted variant show different enzymatic properties in comparison to the viral endonuclease PA.Skewed B cells in chronic hepatitis C virus infection maintain their ability to respond to virus-induced activation.HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients.Phylogenetic analysis of HIV type 1 CRF02_AG in multiple genes in Italian and African patients living in Italy.Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility.Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009.Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity.Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy.NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients.Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection.Occurrence of Extended Spectrum β-Lactamases, KPC-Type, and MCR-1.2-Producing Enterobacteriaceae from Wells, River Water, and Wastewater Treatment Plants in Oltrepò Pavese Area, Northern Italy.Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?Changing circulation rate of human metapneumovirus strains and types among hospitalized pediatric patients during three consecutive winter-spring seasons. Brief report.Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants.Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV.12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals.Higher levels of HIV DNA in memory and naive CD4(+) T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART.
P50
Q30393218-198CC469-4B2F-4957-89EE-4E1494BEECB4Q33758603-F99C1FEC-4967-467C-9F75-77FE573E6445Q34081828-D1DE4670-0B7F-4009-B8E1-39E3EE5F336CQ34149154-4632C6FC-802F-44CD-8A13-47F582B4D42DQ35069514-D9CE011E-2AFF-4B31-AD0D-368908EB0F15Q35867094-EC2CC55A-B862-4057-B72F-417FB75D3421Q36576849-2E74803D-9F61-40BB-AA5C-2A213E615920Q37426527-4B781891-E946-491C-8EA8-99138A43D469Q37427096-A9C61299-988F-4EB6-9FEC-9D9AF3769ED6Q37530942-9DD442D0-070D-43BC-A190-72A7598B2FC2Q38972095-6459577E-B06F-47B8-89E6-0B45D2F87211Q39337307-BC21528F-6AED-4FDA-893B-F2028199B282Q39519625-2F012924-5E48-41A1-A109-D650B1558322Q40241218-B4A1A35F-1BF1-4767-BF32-DBDC1134CE38Q40373017-B0D88328-5AE8-443E-A53D-6610109A9C8AQ40397174-6DD1B858-CD0F-4E0E-8B6D-059DF35FCDBFQ40425060-B1D38966-3CA4-4AD1-9881-EF643D56DFF7Q40870028-F06F0046-C6DC-4B4B-8736-C64764A14A05Q41347441-0ED442D7-E4CA-4F3A-BCD7-2677827680CFQ41725485-2FFDCA6E-F18D-41FD-941E-A8883DA7FFAEQ42094831-C5D396A3-BC67-4604-B15D-30D70B6C2643Q42214894-DFB99B4C-A247-46FD-B46F-941EDB4D9ED5Q43199937-2B0911D4-F10D-4618-8231-EC503B211B1AQ43482398-CA8B0032-FBBF-4051-A0F1-A406A100046BQ43520841-F893C6D2-7E75-4F2F-BD97-5A8429FE5BC0Q43630493-CADC8972-46D4-4DAC-B067-7E4966A5EEC9Q44324702-6D3A2FEC-1BC9-4BF4-9B7E-C103EC86D04EQ45360877-FD226ED0-0760-4A36-8426-32FDC6652279Q45401764-DD9EAB4C-4F38-48D9-8F03-0668263C98B6Q45729780-D66FEBE4-E859-4B3A-AE64-593693DE2578Q45757961-3628A96D-3906-4358-98F5-2FB71F606DAFQ46253963-D32A7AA0-8187-4387-8DE0-34E5ED5A98BFQ47121746-98EFA24D-4F2E-4380-9C9B-3DC23683A972Q47633959-E33B6BBC-79EC-4101-83AB-3473CA8A874AQ47772700-7073211F-33B6-4852-8436-0D8C8A39947FQ47881442-401A6457-8B90-46D6-B845-8C95F32DFFD5Q50552089-ABFDEE88-1476-4139-BC12-8D90491C4B6AQ51745126-E5FFBA71-89E4-409D-8533-341D3CC79171Q51965374-67F36FE6-26C7-43D2-B384-A730EA12131BQ52019344-AD692387-1630-489D-82B4-512E3208846D
P50
description
researcher
@en
name
Stefania Paolucci
@en
Stefania Paolucci
@nl
type
label
Stefania Paolucci
@en
Stefania Paolucci
@nl
prefLabel
Stefania Paolucci
@en
Stefania Paolucci
@nl
P106
P31
P496
0000-0001-8447-8586